AUTUMN SCHNEIDER: Open Payments
NPI 1811538218 · PARIS, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$590 in 31 payments from 11 companies in 2025. Trend: 2023 $474 · 2024 $321 · 2025 $590
Food & beverage: $590
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $129 |
| E.R. Squibb & Sons, L.L.C. | 2 | $91 |
| Boston Scientific Corporation | 3 | $68 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 5 | $64 |
| Novartis Pharmaceuticals Corporation | 3 | $62 |
| Amgen Inc. | 3 | $48 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Novo Nordisk Inc | 2 | $31 |
| Merck Sharp & Dohme LLC | 1 | $20 |
| Chiesi USA, Inc. | 1 | $18 |
Products named: Kerendia, LifeVest, LEQVIO, CDS - MCT/CEM Monitoring, EVKEEZA, REPATHA, VERQUVO, OTEZLA.
Industry payments across KY — which companies pay providers there.
